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H istorically, the introduction of classical bone marrow transplantation into this country some thirty years ago centered on adults with problems in the form of rejection and acute and chronic grafttversusthost disease contributing to morbidity and mortality. 1, 2 Despite our early involvement in the use of cyclosporine A as a new generation immunosuppressive agent, these complications continued, although of det t creased incidence and severity. 3 The major advance in their reversal was initiation of a series of studies that eventually led to the landmark description of ex vivo Ttcell depletion using Campath monoclonal antibodt t
INTRODUCTION AND STUDY DESIGN:
We conducted a retrospective analysis of consecutive referrals of pa-tients under 18 years of age undergoing immunohematopoietic stem cell transplantation to assess the influence of age, diagnosis, graft type and gender on survival. We also contrasted program activity and outcome to that reported from a state hospital in the same geographical area over a comparable period. METHODS: conditioning employed either a sequential combination of fractionated 12Gy whole body and 6Gy total nodal irradiation separated by 120mg/kg of cyclophosphamide in patients over 15 years of age. alternatively, the latter agent was combined initially with oral busulphan and later the intravenous equivalent. neuroblastoma cases were prepared using a different regimen. in allografts the harvested product underwent ex vivo t-cell deple-tion with the humanized version of anti-cd 52 monoclonal antibody designated campath 1h. no additional immunosuppression was given except where matched unrelated volunteer donors were employed. RESULTS: sixty-eight procedures were carried out in 61 patients over a 6-year period. of 11 with acute myeloid leukemia, 8 are alive and well whereas 8 of the 14 with the lymphoblastic variant have died. of the remaining 12 with hematologic malignancy, all but 2 are alive. ten of the 17 with aplasia are alive as are all with thalassemia or sickle cell disease. none of the four variables tested affected survival. CONCLUSION: our analysis indicates that the standardized preparative regimen, coupled with a now well-es-tablished immunosuppressive regimen, is as effective in patients under 18 years of age as in adults. our analysis also indicates that in a resource-scarce or developing country, it is mandatory to limit high-risk and relatively expensive procedures to active teams that enjoy international accreditation, whether these be in the state or private sector. ies 4 and our experience continues to accummulate. 5t7 Notwithstanding the unquestioned benefits, and in contrast to elsewhere in the world, there remained a subt t stantial local resistance to subjecting children to what was perceived as a still unduly hazardous undertaking! Nevertheless, within 10 years of commencement, it bet t came more generally appreciated that idiopathic and irreversible aplasia could only be cured by allografting whereas a variable response was obtained with antit lymphocyte globulin and hightdose methylprednisot t lone. 8, 9 From that time the eligibility for grafting was modified to accommodate younger cases and our initial results that were reported whilst still at Groote Schuur Hospital 10t12 have recently been updated. 13 From January 1995, our established and approved protocols were transferred in toto to a custom built facility in the private sector. In the new location cont t secutive procedures continue to be reported to the Center for International Blood and Marrow Transplant Research and this specific team was again retaccredt t ited in January 2003, thereby maintaining a 30tyear unbroken record of achievement. Thus, the following analysis from the Department of Haematology and the Bone Marrow Transplantation Unit incorporating The Searll Research Laboratory for Cellular and Molecular Biology at the Constantiaberg MeditClinic brings int t ternational perspective to outcomes in the pediatric age group undergoing immunohematopoietic grafting in South Africa.
The available facilities, when we pioneered the use of this technology in the Groote Schuur Hospital at the beginning of 1972, were such that management of the young was logistically difficult. This hurdle was overcome by providing separate rooms when the newly dedicated reverse isolation unit was designed and then commissioned in 1982. Given the upgraded physical plant, and expansion of staff to include a social worker, a physician and a psychiatrist with interest in adolest t cents, it became a realistic option with the first child grafted in 1978. The multitdisciplinary approach was consolidated by participation of Dr Paul Rogers followt t ing his return after a period of overseas postgraduate training. 14, 15 With the relocation of this fully integrated group to an independent academic center it was soon demont t strated, both logistically and functionally, that there was no impediment to providing costly and high technology activities in such an environment. 16t18 Continuing outt t come analysis from this reverse isolation unit, staffed by nurses trained in all relevant facets with a virtually fullt time commitment from pediatricians already in the host t pital, rapidly confirmed the feasibility of using advanced protocols approved by Institutional Review Board for conventionally defined indications, in a protected envit t ronment dedicated to tertiary hematologic care. 17 In the last decade a number of refinements have become standard practice. Among these was the use of matched or minimally mismatched family memt t bers and the availability of donations from histocomt t patible, unrelated volunteers via the South African Marrow Donor Registry. 18 To this end, center desigt t nation by the European Group for Blood and Marrow Transplantation 19 and by the National Marrow Donor Programme followed. 20 A priority remains the commitment to whatever innovation is necessary to keep abreast of relevant adt t vances such as the study of chimerism using short tert t minal repeat assay. 21 This has included exploring the role in thalassemia, sickle cell disease, 22 mucopolysact t charidoses, 23 common variable immunodeficiency, 24 and Fanconi anaemia. 25, 26 The latter is currently linked to gene therapy being evaluated jointly with Professor Chris Walsh initially in North Carolina, 27 and now curt t rently in New York, where special attention has been given to complications from older forms of conditiont t ing that included cyclophosphamide or, even earlier, rat t diotherapy. Accordingly, this phase has been revised to the use of fludarabine and intravenous busulphan. 28 The latter model is to be tested as the basis for cont t trasting the previously favored myeloablative combinat t tions to primarily immunosuppressive options across the age spectrum. 29, 30 The rationale for this focus lies in harnessing the formidable capacity of the immune system to identify and eradicate tumor cells and cret t ates a platform for the use of immunotherapy based on subsequent delayed or donor lymphocyte infusions. 31 Whether such a theoretically attractive modification will represent a significant advance awaits longer follow up. 32 Among the remaining challenges is the problem of mucositis, which impairs nutritional intake, and has led to a focus on the need for developing a structured approach to nasojejunal feeding rather than the more traditional total parenteral approach (Wood, O'Keefe, Jacobs, Dubrovskaya, unpublished) Additionally, there is an increasing appreciation of infections particularly cytomegaloviremia that may progress to organ involvet t ment as in pneumonitis and this, together with other infections, possibly related to the use of monoclonal ant t tibodies, 33t35 predicated the ongoing study of immunot t logic reconstitution and viral surveillance with proactive ganciclovir therapy. 36 It is against this brief historical outline that outcome in children is presented: the corresponding results in those over 18 years are in preparation ( Jacobs, Wood, Juritz, unpublished).
STUDY DESIGN
Our analysis is tabulated for consecutive entries seen in the 6tyear period to allow comparison to updated results from the State. 13 Additionally, we explored the practicality of operating such a facility, with the specific focus on childhood referrals, outside the confines of the usual base in teaching hospitals. With appropriate att t tention to financial imperatives and, notwithstanding the evertconstricting focus of changing health care, it original research report peDiATriC SCT in CApe TOwn Hematol Oncol Stem Cell Ther 1(2) April 2008 hemoncstem.edmgr.com also tests the possibility of maintaining, and continut t ally developing new aspects of this technology in more innovative indications, to keep abreast of worldwide advances. 37, 38 One modification has been a switch from oral to int t travenous busulphan. 39 A further logical step will now be the increasing use of fludarabine as a component of minit or sotcalled reducedtintensity conditioning regit t mens that have, as a backbone, sufficient suppression of the immune system primarily to allow host accept t tance of the incoming graft. The anticipation is that a grafttversustleukemia effect will be retained whilst, at the same time, the more serious consequences of the classical myeloablative regimens will decrease. 40 Furthermore, in addition to confirming the pattern of hematopoietic reconstitution, a secondary endtpoint is that of defining immunologic reconstitution. 41, 42 This endeavor aims to decrease the hazards of infection that notably include those attributable to cytomegalovit t rus. 43,44
METHODS
After recording a detailed history and completing a physical assessment, standard hematologic procedures were employed for a full blood count, 45 aspiration and trephine biopsy. 46 The malignancies were classified ust t ing conventional cytomorphology supplemented by flow cytometry 47 and cytogenetics 48 to precisely det t lineate each case after which treatment was by riskt stratification to standardized protocols. 49, 50 The mat t lignancies were classified according to World Health Organization criteria. 51 Aplasia was similarly categot t rized and in those with Fanconi anaemia, additional studies included chromosomal fragility after exposure to clastogenic agents. 52 Hemoglobinopathy was subdit t vided by electropheresis and appropriate biochemical tests. 53 For donor selection, histocompatibility testing employed conventional methodology and matching between donor and recipient using international stant t dards via the Hub center of the South African Bone Marrow Donor Registry. 19 Donations for matched unrelated volunteers were provided in collaboration with the Anthony Nolan, Australian, German and Leiden Groups as well as The National Marrow Donor Programme. 21 All aspects of the treatment including indication, anticipated benefits and potential risks were fully ext t plained by means of extensive counseling after which written informed consent was obtained. Recipients and donors were assessed to ensure suitability for particit t pation and this included clinical examination and nont invasive cardiac and respiratory testing. Placement of a doubletlumen catheter 54, 55 was followed by nursing in reverse isolation. 56 Selective decontamination of the bowel was performed with daily fluoroquinolone 57 and oral prophylaxis for cytomegalovirus and Pneumocystis carinii, respectively, with acylclovir or valaciclovir 58 and cottrimoxazole, or in the case of allergy, an appropriate equivalent. 59 Conditioning was 12 Gy fractionated total body irt t radiation over 3 days at rates of approximately 10cGy per minute, 60 mg/kg of cyclophosphamide over 2 days with intensive hydration, protection of the urothelium with mesnum and total nodal irradiation at 1.5 Gy over 2 days. 4 The alternative regimen comprised 120 mg/kg of cyclophosphamide combined with 16 mg/kg of oral busulphan, 4,60 or 3.2 mg/kg per day intravenously for 4 days. Patients with Fanconi anemia received cyclot t phosphamide at reduced doses. 61 Irrespective of body weight, a quantitative and qualitatively adequate hart t vest was obtained after mobilization with stimulatory peptides for 5 consecutive days, by using constantly upgraded aphaeresis technology on the Cobe Spectra as previously described. 62, 63 No prophylaxis was employed against grafttversust host disease except in those undergoing matched unt t related donations where cyclosporine was maintained at a therapeutic level for 6 months using the C2 assay 64 and then tapered to zero over the following half year. Nutrition was a high priority and, whilst intravenous supplementation was not used, there was early recourse to finetbore nasojejunal tube feeding when needed, 65, 66 (Wood, O'Keefe, Dubrowsky, Vincent, Jacobs, unpubt t lished).
Comparisons of results between the state and prit t vate hospital were made using Pearson' s chitsquared tests. Survival time after transplant between groups was assessed using KaplantMeier survival curves. Survival times between groups were compared using logtrank tests.
RESULTS
The total number of procedures including retranst t plants 68 at Constantiaberg MeditClinic and 31 at Groote Schuur Hospital. The median age of the pat t tients treated at Constantiaberg was 11.7 years (range 1.7t18.7 years). Hematologic malignancy accounted for 37 cases at Constantiaberg MeditClinic ( larger numbers and additional indications in this series, the populations were comparable. 13 Day 0 was designated as graft infusion. The median time to reach 0.5×10 9 /L and 1.0×10 9 /L neutrophils were 18 days (range, 9t34 days) and 28 days (range, 10t 59 days), respectively. The median time for platelets to reach 25×10 9 /L and 100×10 9 /L was 17 days (range, 5t32 days) and 27 days (range 13t127 days), respect t tively. 67, 68 Transplanttrelated mortality was death attributable to infection within the first 100 days in the absence of any disease recurrence 29 and it accounted for all the events apart from one due to dilated cardiomyopathy. An unusual variant of the acute syndrome of graftt versusthost disease occurred within the first 6 months that was distinctly different from the classical chronic disease. 68, 69 This was regarded as a forme fruste due to altered immune status consequent upon the ex vivo Tt cell depletion 70, 71 and occurred in only two cases with successful reversal using topical steroids combined with a short course of oral prednisone. 72, 73 Cytomegalovirus was demonstrated using the PP 65 assay in two instances that were treated intravenously. One died and in the second no further isolates were present at two weeks although a further 14 days of outt t patient oral antiviral treatment followed. Anorexia with nausea and vomiting was readily controlled with serot t tonin and dopamine receptor antagonists although oct t casionally prochlorperazine was added. 74 Diarrhea was assessed with stool culture and treatment of Clostridium difficile when present; 75 otherwise simple motility modt t ulation using loperamide hydrochloride, a combination of kaolin with bismuth carbonate, pectin coupled to chlorodyne was used. 76 Particular attention has focused on maintaining optimum fluid and electrolyte balance. 77 Pain was a major problem when mucositis occurred and initially required oral or intravenous opiates. 78 This symptom has been dramatically reduced by the use of sucralfate. 79
Hematologic malignancies (Table 1)
Acute myeloid leukemia (11 procedures, 10 patients at Constantiaberg MeditClinic) (9 procedures, 9 pat t tients at Groote Schuur Hospital), once diseasetfree, was treated on this regimen. Nine were allogeneic. One died from cardiomyopathy, a second died in relapse and a third died from recurrence after a second technically successful transplant. Acute lymphoblastic leukemia, most of whom were in second remission (14 procet t dures, 11 patients at Constantiaberg) (4 procedures, 4 patients at Groote Schuur), were autografted in 9, of whom 5 died in relapse. Of the allografts (n=2) from siblings 1 died of aspergillosis. A further 3 employed matched unrelated volunteers with 1 dying from mult t tiorgan failure and 1 with recurrent disease. Patients with juvenile myelomonocytic leukemia (1 procedure, 1 patient at Constantiaberg) (1 procedure, 1 patient at Groote Schuur) remain alive. Chronic granulocytic leukemia (6 procedures, 5 patients at Constantiaberg) (2 procedures, 2 patients at Groote Schuur Hospital) was autografted in one who did not achieve cytogenetic remission and after matched unrelated volunteer donat t tion achieved this status by molecular criteria. One synt t geneic, three sibling allografts and one further unrelated graft were successful of which one died from cytomegat t loviral pneumonitis. The remainder were disease free at the time of writing. Hodgkin (2 procedures, 2 patients at Constantiaberg) (n=0 at Groote Schuur) and other lymphomas (3 procedures, 3 patients at Constantiaberg) (n=0 at Groote Schuur) received allografts in 2 and aut t tologous reinfusion in 3 case. One died from infection and 4 remain in remission.
Benign Diseases (Table 2)
In cases of aplastic anaemia (6 procedures, 5 patients at Constantiaberg MeditClinic) (10 procedures, 7 pat t tients at Groote Schuur Hospital), 4 were allografted and 3 were alive and well at the time of writing. One failed to engraft and despite a repeat procedure died from septicemia. Two received matched unrelated dot t nations; 1 died from septicemia and the other is well. Fanconi anemia cases (11 procedures, 10 patients at Constantiaberg) (5 procedures, 4 patients at Groote Schuur) were allografted. One required a second att t tempt and died with septicaemia, another developed secondary lymphoproliferative disorder and two died from cytomegaloviral infection and another from mult t tiorgan dysfunction. In this category, damage to the orot t pharynx and gastrointestinal tract made enteral feeding unreliable and added the costs for limited periods of tot t tal parenteral nutrition. 80, 81 Hemoglobinopathy (6 prot t cedures, 6 patients at Constantiaberg) (n=0 at Groote Schuur) were all allografted, and were alive and well at the time of writing although two still had disease prest t ent on sensitive biochemical testing.
A miscellaneous group was made up of 1 patient with germ cell tumor that was allografted and died from cytomegaloviral pneumonitis, and 5 patients with neuroblastoma that were autografted and 1 patient died with relapse. Figure 1 . kaplan-Meier survival for all patients. kaplan-Meier analysis shows that at 6.8 years there is a stable plateau consistent with cure. it is notable that results are similar for idiopathic aplasia, Fanconi anaemia and acute myeloid leukaemia with non-significant differences for lymphoblastic leukemia and the remaining cases. There is also no difference in outcome for graft source, but a slight benefit for the female gender, which did not attain statistical significance.
dosis and another with immunodeficiency remained alive and well at the time of writing.
Overall Survival
Overall survival was 60% at 7 years of followtup (n=59 at Constantiaberg MeditClinic) ( Figure 1 ). Notably, survival was similar for idiopathic aplasia, Fanconi anet t mia and acute myeloid leukemia with nontsignificant differences for lymphoblastic leukemia and the remaint t ing cases. There is also no difference in outcome by graft source, but a slight benefit for the female gender, which did not attain statistical significance. Given the small numbers it is not surprising that none of the variables achieved significance. Quality of life studies 82, 83 were not formally carried out in this investigation.
DISCUSSION
These results are comparable to published first world outcomes. Our analysis allows four conclusions. Firstly, the scientific and ethical aspects of immunohematot t poietic stem cell transplantation, whether the graft is derived from bone marrow or peripheral blood, when conducted by an appropriately constituted and funct t tioning multidisciplinary team, operating in a private academic center, demonstrably meets worldwide stant t dards of practice. This is reflected in satisfactory audit with ongoing retaccreditation of this particular team by the International and Autologous Bone Marrow Transplant Registries now combined as the Centre for International Blood and Marrow Transplant Research with endorsement as a transplant, harvest and donor center by the European Group for Blood and Bone Marrow Transplantation as well as for performing these procedures as designated by the North American National Marrow Donor Program.
Secondly, while indications continue to undergo redefinition, correct case selection is imperative, if the best needs of the community are to be served. Thus, act t cess to the technology must be widely available and, by definition, this includes responsible resource allocation between state and private sectors. To this end it is cont t structive to contrast the present experience to our init t tial reports 10t12 that were recently updated from a state hospital. 13 It can be seen that there is no substantial dift t ference in demography, procedure or results other than, in the current series, somewhat larger numbers, wider indications, use of intravenous busulphan and inclusion of matched unrelated volunteer donors. Of relevance is that, at least in siblings, further immunosuppression is not needed after ex vivo Ttcell depletion and this transt t lates to financial cost saving with possibly a decrease in morbidity. It therefore follows that even when alternative graft sources are used, the relatively high initial costs are clearly offset by the potential for cure and so justify the maintenance and indeed ongoing development of such a therapeutic option. This situation differs significantly from regimens using unmanipulated grafts which would then typically include cyclosporine A, shorttcourse methotrexate and often corticosteroids as necessary to control rejection and blunt acute as well as chronic grafttversusthost disease. To accommodate these varit t ables identification of teams that fully and consistently meet standards, of which the centerteffect necessitating a minimal number of procedures to comply with agreed activity, is mandatory to prevent this important treatt t ment option becoming discredited as a result of inadt t equate performance. Whether a mechanism for national scrutiny and registration can be established is currently conceivable but whether it would ever become acceptt t able in the wider world remains moot. Currently at least compliance with the approved guidelines from The North American Foundation for the Accreditation of Hematopoietic Stem Cell Therapy 84 as well as the Joint Accreditation Committee of the International Society for Hematopoietic Therapy and Graft Engineering in Europe and the European Group for Blood and Marrow Transplantation 85 would be a desirable starting point. In this context there is also the crucial balance between original research report peDiATriC SCT in CApe TOwn the undoubted need and funding provided by managed health care required to allow private sector programs to match state activities with the latter having a reciprot t cal obligation to provide for individuals with limited resources. In these circumstances utilization of those procedures should be shared on the basis of resource availability for individual patient groups.
Thirdly is the crucial caveat that only peertret t viewed protocols, having undergone scrutiny by Ethics and Research Committees coupled with Institutional Review Board endorsement, are supported. These need, in a single center by definition, to have the expertise and flexibility to accommodate appropriate patient categot t ries and to do so irrespective of age. Given the constant revision of the role that such interventions generate an acute awareness of shifting entry int t dications is vital. For example there is now appropriate and decreasing referral in acute myeloid leukemia when the presence of specific, or good risk, cytogenetic markt t ers show equal outcome with optimum chemotherapy. Furthermore, the competing role of small molecules such as retinoic acid and arsenic in progranulocytic tut t mors on the one hand and signal transduction inhibit t tion in chronic granulocytic leukemia using imatinib on the other, alter the previously automatic inclusion of stem cell transplantation in treatment algorithms. There needs to be a consciousness that these expensive but pot t tentially curative interventions retain a role in Hodgkin and other lymphomas, but outside clinical trials, preft t erably international, raise serious reservations about uncritical and random usage. Concerns focus on small numbers of cases in unregistered practice by occasional therapists not reporting results. Implicit in such ongot t ing scrutiny is an obligation for unit or team recognition based upon outcome analysis and peer review accountt t ability raising the spectre of there being some sensible restriction to preferred providers or designated units. These need to be defined by published survival data and, most certainly, not the alternative, but convenient choice of only cost as the defining factor for sotcalled preferred providers! Fourthly, among the areas of expanding interest are the solid tumors. The present data are too small for interpretation and only establish technical feasibility. The continuation of this commitment, perhaps more so than in conventional usage, should not be restricted but rather encouraged, within the context of thoughtful, registered and multicenter trials.
CONCLUSION
This interim analysis of ongoing studies presents outcomes consistent with international standards of practice and supports the appropriateness of cont t tinuing to provide immunohematopoietic stem cell transplantation to properly selected cases throughout South Africa. This subtSaharan stance could serve as a model for other undertresourced countries worldwide. Predictably no difference in results could be found bet t tween those from this private academic center or a state hospital emphasizing that allocation of transplantation should be shared as dictated by availability of resources in each sector. Furthermore, since these are uniform irt t respective of age, separate pediatric units are difficult to justify in the face of a limited and ever deteriorating economic climate. Whilst acknowledging substantial financial costs and morbidity and mortality, these are offset by the curative potential of this form of treatt t ment and, accordingly, they remain an obligation, but should be provided, and fully supported, only in those centers that meet stringent international criteria, int t cluding regular audit, and consequently enjoy ongoing accreditation by major registries worldwide.
